Turning Point Therapeutics, Inc.

... ...
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 0.16%36.760.9%$1163.47m
JNJJohnson & Johnson 1.30%162.390.7%$1091.23m
LLYEli Lilly & Co. 3.00%196.501.1%$724.53m
ABBVAbbVie, Inc. 1.28%111.941.9%$712.39m
MRKMerck & Co., Inc. -0.20%83.210.7%$682.52m
BMYBristol-Myers Squibb Co. 0.48%66.861.0%$680.87m
AZNAstraZeneca Plc 2.22%52.481.2%$644.16m
ARCTArcturus Therapeutics Holdings, Inc. 12.25%67.000.0%$230.38m
VTRSViatris, Inc. 1.58%17.320.0%$195.09m
RPRXRoyalty Pharma Plc 1.66%52.810.2%$176.76m
NVSNovartis AG 0.77%96.370.2%$171.95m
GSKGlaxoSmithKline Plc 0.20%38.550.2%$140.50m
SNYSanofi 2.41%50.580.2%$116.52m
RGENRepligen Corp. 4.68%225.546.9%$79.19m
NVONovo Nordisk A/S 1.65%73.220.1%$72.00m

Company Profile

Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.